Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06747949 · ClinicalTrials.gov registry record · Phase 3

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

A Phase 3 study of Sjögren's Syndrome, sponsored by Amgen.

Recruiting
Registry status
Phase 3
Development phase
844
Enrollment target
20
Study locations

NCT06747949: Recruiting Phase 3 study of Sjögren's Syndrome, sponsored by Amgen.

NCT06747949 is a Phase 3 study of Sjögren's Syndrome that is actively recruiting participants, run by Amgen. The registered enrollment target is 844 participants, above the 297-participant average among 4 other Sjögren's Syndrome trials with a reported enrollment target (184% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06747949, a Phase 3 study of Sjögren's Syndrome, is actively recruiting participants, sponsored by Amgen.

RECRUITING
Registry status
Phase 3
Development phase
844 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.

Primary Outcome

Includes treatment emergent serious adverse events (TESAEs) and adverse events of special interest (AESIs).

Conditions Studied

Interventions

  • DRUG Dazodalibep

Study Locations (20)

Arizona

  • Arizona Arthritis & Rheumatology Associates - Avondale - Avondale
  • Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln - Flagstaff
  • Arizona Arthritis and Rheumatology Associates - Gilbert - 3645 S Rome St - Gilbert
  • Arizona Arthritis and Rheumatology Associates - Glendale - 5681 W Beverly Ln - Glendale
  • Arizona Arthritis and Rheumatology Associates - Tucson - 2001 W Orange Grove Rd - Tucson

Florida

  • Bradenton Research Center Inc - Bradenton
  • Clinical Research of West Florida Inc - Clearwater - Clearwater
  • BayCare Medical Group Primary Care and Rheumatology - Tampa - Tampa

North Carolina

  • Arthritis and Osteoporosis Consultants of The Carolinas - Charlotte - 1918 Randolph Rd - Charlotte
  • Duke Early Phase Clinical Research Unit - PPDS - Durham
  • Onsite Clinical Solutions, LLC - Salisbury - Salisbury

California

  • Samy Metyas MD Inc - Covina
  • UCSD Altman Clinical and Translational Research Institute Building - La Jolla

Ohio

  • Arthritis & Osteoporosis Center of Southwest Ohio - Miamisburg - Miamisburg
  • University of Toledo Medical Center - Toledo

Colorado

  • Tekton Research, LLC - 2121 E Harmony Rd - PPDS - Fort Collins

Massachusetts

  • Tufts University School of Dental Medicine - Boston

Michigan

  • Shores Rheumatology - Saint Clair Shores

Trial Details

FieldValue
Enrollment Target 844 participants
Start Date 2025-02-25
Est. Completion 2029-12-11
Phase Phase 3
Amgen

558 total trials

What NCT06747949 shows while recruiting

NCT06747949 is an interventional study that assigns participants to a tested intervention. The registered 844 participants enrollment target is mid-sized for trials with a published cap, above the 297-participant average among 4 other Sjögren's Syndrome trials with a reported enrollment target (184% higher).

The record links to 1 condition, with Sjögren's Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Dazodalibep is the first listed.

NCT06747949 names 20 study sites across 10 states, led by Arizona, Florida, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06747949 about?

NCT06747949 is a clinical study titled "A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)". The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.

What is the current status of trial NCT06747949?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 844 participants. The study started on 2025-02-25. Estimated completion is 2029-12-11.

What conditions does trial NCT06747949 study?

This clinical trial studies the following conditions: Sjögren's Syndrome.

What interventions are being tested in trial NCT06747949?

The interventions under investigation include: Dazodalibep (DRUG).

Who is sponsoring clinical trial NCT06747949?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06747949 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sjögren's Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02757859 · 845 participants · NA

    High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery

  • NCT06439979 · 843 participants · NA

    Rural Adult and Youth Sun Protection Study

  • NCT06027788 · 842 participants · NA

    CTSN Embolic Protection Trial

  • NCT07142408 · 848 participants · Phase 3

    The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06747949, the US trial registry maintained by the National Library of Medicine. NCT06747949 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.